A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

Sponsor
AbbVie
Study ID
NCT07136467
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study is to assess the burden of disease in adolescent and adult participants with moderate or severe alopecia areata (AA), non-segmental vitiligo (NSV), or moderate to severe hidradenitis suppurativa (HS) in a large global real-world participant population.

Key Dates

First listed
Aug 22, 2025
Start date
Sep 2, 2025
Status verified
Feb 2026
Primary completion
Aug 31, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
2,795 participants (estimated)

Arms

  • Arm: Participants with Vitiligo
    Participants with vitiligo will undergo a single-visit data collection per routine clinical practice
  • Arm: Participants with Alopecia Areata
    Participants with alopecia areata will undergo a single-visit data collection per routine clinical practice
  • Arm: Participants with Hidradenitis Suppurativa
    Participants with hidradenitis suppurativa will undergo a single-visit data collection per routine clinical practice

Primary Outcome Measure

Alopecia Areata (AA) symptoms affecting quality of life and daily functioning, assessed by the Alopecia Areata Symptom Impact Scale (AASIS) AA only [ Time Frame: Up to Day 1 ]

Central Contacts

Find similar trials

Nationwide
Hidradenitis suppurativa trialsDermatology trialsRheumatology trialsAutoimmune disease trials

Related Studies